Advertisement

Topics

Pfizer Launches 2016 Annual Review

06:00 EDT 13 Mar 2017 | 3blmedia - Health

SOURCE: Pfizer

DESCRIPTION:

Today, Pfizer launched its 2016 Annual Review, which provides an in-depth look at how the company is working to accelerate patient impact. The report provides an overview of the company’s financial, social and environmental performance throughout last year.

In 2016, Pfizer made significant progress in the execution of our strategy and the achievement of our mission to become the premier biopharmaceutical company in the industry by the end of this decade. It was a strong year with substantial contributions across every part of Pfizer’s organization. Highlights throughout the year include:

  • Sharpened focus on areas of biomedical R&D that will give us the best promise of success

  • Collaboration to enhance the medicines, vaccines and therapies in our pipeline

  • Solid execution to drive strong financial performance on behalf of our shareholders

  • Work to improve global health by making our therapies more accessible

  • A culture that is centered upon accountability, confidence and resiliency

Learn more about the ways we’re helping individuals everywhere live healthier lives at www.pfizer.com/annual.

 

Tweet me: .@Pfizer 2016 Annual Review highlights impact on global health, environment, and more http://bit.ly/2m8p3Ab #CSR

KEYWORDS: Reports, Business & Trade, Pfizer, Corporate Social Responsibility, sustainability

Original Article: Pfizer Launches 2016 Annual Review

NEXT ARTICLE

More From BioPortfolio on "Pfizer Launches 2016 Annual Review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...